Skip to main content Start of content
An email address associated with the Government of Canada or the Parliament of Canada may not be used to create, support, or sign an e-petition.
Subscribe to RSS Feed Subscribe to RSS Feed

e-1635 (Health care services)

42nd Parliament
Initiated by Kira Palmer from Calgary, Alberta, on April 23, 2018, at 4:44 p.m. (EDT)
keywords
Health care system
Pharmaceuticals
Spinal muscular atrophy
Presented to the House of Commons

Petition to the Government of Canada

Whereas:
  • 15 other countries, including the United States, France, Germany, Sweden and Italy, have already approved Spinraza as a treatment for patients with Spinal Muscular Atrophy (SMA);
  • Health Canada has already approved Spinraza for the treatment of SMA;
  • Through clinical evidence, Spinraza has shown to reduce the risk of death and improve motor and respiratory functions;
  • Long-term monetary and social costs to the provinces without the use of Spinraza will be higher due to eventual invasive and costly procedures that otherwise could potentially be avoided;
  • Treatment of SMA of any type should be started as early as possible to prevent disease progression and ultimately save life as well as improve quality of life.
We, the undersigned, citizens and residents of Canada, call upon the Government of Canada to overturn the decision of CADTH and ensure Spinraza is approved for all types of SMA so that provincial governments can negotiate for a price for all Canadians with SMA.
Calgary Shepard
Conservative
Alberta
Petition presented to the House of Commons on October 17, 2018 (Petition No. 421-02756)
Government response tabled on
Open for signature : April 23, 2018, at 4:44 p.m. (EDT)
Closed for signature : August 21, 2018, at 4:44 p.m. (EDT)
Province / Territory
Signatures
Alberta
1254
British Columbia
171
Manitoba
107
New Brunswick
52
Newfoundland and Labrador
4
Nova Scotia
13
Ontario
448
Prince Edward Island
1
Quebec
33
Saskatchewan
507
Other Countries
9
Disclaimer regarding e-petitions